secwatch.observer — SEC 8-K summary
======================================

Issuer:     RECURSION PHARMACEUTICALS, INC. (RXRX)
CIK:        0001601830
Form:       8-K
Filed at:   2024-09-03T23:59:59+00:00
Accession:  0001601830-24-000148
Event type: other_material
Sentiment:  neutral
Materiality: 0.75
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Recursion reports top-line SYCAMORE data, files Exscientia financials for proposed merger
--------------------------------------------------------------------------------

- SYCAMORE Phase 2 trial for REC-994 in symptomatic CCM patients: top-line results announced Sept 3, 2024 (press release as Exhibit 99.2).
- Filed audited financials of Exscientia for FY2023 and FY2022 (Exhibit 99.3) and unaudited interim statements for H1 2024 (Exhibit 99.4).
- Filed pro forma condensed combined balance sheet as of June 30, 2024 and pro forma statements of operations (Exhibit 99.5).
- Transaction closing deadline Aug 8, 2025; termination fees: Recursion $58.77M, Exscientia $6.88M; subject to HSR, court, stockholder votes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1601830/000160183024000148/0001601830-24-000148-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1601830/000160183024000148/rxrx-20240903.htm
  HTML page:      https://secwatch.observer/filing/0001601830-24-000148

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer